SAM
BMRN icon

Symphony Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Symphony Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-10,000
Closed -$704K – 418
2013
Q4 		$704K Buy
10,000
+2,500
+33% +$170K 0.05% 239
2013
Q3 		$540K Buy
+7,500
New +$498K 0.05% 295

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Symphony Asset Management's BMRN Position: Q3 2018 in Review

Symphony Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 2,653 shares — an estimated $215K sold.

Symphony Asset Management first reported a position in BMRN in Q4 2013 and held it in 12 quarters. The position peaked at $614K in Q3 2017. 460 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

  • Symphony Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Symphony Asset Management sold 2,653 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $215K.
  • Symphony Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 12 quarters.
  • Symphony Asset Management's BioMarin Pharmaceuticals position peaked at $614K in Q3 2017.
  • 460 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Symphony Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.